Altea gains US grant for insulin delivery device:
This article was originally published in Clinica
Altea Development has received a phase II grant from the US National Institute of Diabetes and Digestive and Kidney Diseases to assess its MicroPor system for the noninvasive delivery of insulin. The Atlanta, Georgia firm will use the $944,000 grant to develop the device for the painless delivery of insulin as either a basal infusion throughout the day or as an on-demand bolus at mealtime. The MicroPor technology is a patch-based system that creates microscopic pores in the outermost skin layer to enable the systemic uptake of topically applied drugs.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.